A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

NCT02316106 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: daratumumab
DRUG: daratumumab
DRUG: daratumumab

Sponsor

Janssen Research & Development, LLC